Iodine-124

Phase 2Radiopharmaceutical

SStanford University

Iodine-124 is one of 50 small molecule programs targeting Thyroid Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Thyroid CarcinomaRecruiting

Thyroid CancerRecruiting

Thyroid CarcinomaPhase 1

Recruiting

Thyroid CancerPhase 2

Recruiting

Competition

Competitive Landscape

65 competitors in Thyroid Cancer

#DrugCompanyPhaseTrials

Lenvima

Eisai

Approved

20 2

Keytruda

Merck & Co.

Approved

9 3

Retevmo

Eli Lilly

Approved

3 4

Rozlytrek

Roche

Approved

2 5

Caprelsa

GGenzyme, a Sanofi Company

Approved

10 6

Gemzar

Nexavar

12 8

Mekinist

Novartis

Phase 3

8 9

Farydak

Alimta

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Thyroid Carcinoma

NCT03647358

Clinical

Trials by Indication[1]

Recurrent1 trial

Comparison of I-124 PET/CT, F-18 FDG PET/CT & I-123 Whole Body Scintigraphy for Recurrent Thyroid CA

Withdrawn·SStanford University··NCT00373711

Breast Cancer1 trial

Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT

Terminated·SStanford University·Phase 1·NCT00725946·7 enrolled

Thyroid Cancer1 trial

Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer

Recruiting·TThomas Hope·Phase 2·NCT06961084·62 enrolled

Thyroid Carcinoma1 trial

Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT03647358·75 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Iodine-124. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Iodine-124 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Iodine-124. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Stanford University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Radiopharmaceutical[2]
Highest Phase: Phase 2[1]
Company: SStanford University

Iodine-124

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Recurrent1 trial

Breast Cancer1 trial

Thyroid Cancer1 trial

Thyroid Carcinoma1 trial

References

Drug Info

Quick Facts

Related News